Omada is better funded than its digital health rival Livongo, but can it achieve a similar valuation?
At the US liver conference Inventiva will make a case for PPAR agonism, while Novo Nordisk and Gilead’s combo will be scrutinised in Nash.
Novo’s late-stage pipeline is set to balloon with three new pivotal trials planned; data due in Alzheimer’s could add a whole new storyline.
Bamlanivimab bucks could help Lilly bounce back from a soft third quarter, but diabetes is the big focus.
Pivotal data on finerenone might see it approved, but competing in the market will be trickier.
With the previous incumbent withdrawn from the market Ascendis hails a new hormone replacement for hypoparathyroidism.